Navigation Links
The current state of lung cancer treatment
Date:12/11/2012

A review in the December issue of the journal Archives of Pathology & Laboratory Medicine by Paul Bunn Jr, MD, University of Colorado Cancer Center investigator and past president of ASCO, IASLC and AACI describes the current state of lung cancer care.

"We're in a new paradigm in which we realize this top cause of cancer deaths is actually a number of related diseases, each potentially with its own cause and cure," Bunn says.

The review describes the shift from blanketing lung cancer with radiation and chemotherapy, to targeting the specific genetic mutations that cause lung cancer's many varieties. The first of these oncogenic lung cancer mutations to be exploited by a drug was the epidermal growth factor receptor (EGFR), described in 2004 and targeted by the drugs erlotinib and gefitinib. Then in 2007 the oncogenic ALK/EML4 fusion protein was described, and is now targeted by the drug crizotinib, which earned FDA approval in 2011. Drugs in the development pipeline target a handful of additional lung-cancer-causing mutations including KRAS, HER2/neu, BRAF, NRAF, and ROS.

"Pathologists used to define lung cancer as one of four types, based on its appearance," Bunn says, "but it's much more heterogenous than that. Some of these driver mutations may only be present in 1 or 2 percent of the lung cancer population, and mutations in combination may make for hundreds of species of the disease, each with its own response characteristics to targeted drugs and drug combinations."

"Whole exome sequencing shows there are about 300 mutations in the average lung cancer," Bunn says. "You may have an EGFR mutation driving the cancer, but then the other 299 mutations may help define who will do well on an EGFR inhibitor."

Bunn points out that in the lung cancer varieties whose driver oncogenes can be matched with targeted therapy, we tend to see 70-80 percent patient response as opposed to 20-30 percent response to traditional chemotherapies, and with much reduced side effects.

But with this great promise of picking off cancer varieties one-by-one according to their oncogenes comes the challenge of testing drugs that are effective in perhaps only one of every 100 lung cancer patients. The challenge is twofold: enrolling enough patients on a clinical trial to make the results meaningful, and securing funding for a trial in which the drug will only be marketable to a small slice of the lung cancer population.

"How do you get drug approvals for what we'd normally call orphan diseases?" Bunn asks.

Then, Bunn points to the major challenge of staying ahead of lung cancer as it mutates in response to these targeted first-line drugs. "Targeted therapies don't cure patients yet," Bunn says. Instead, lung cancer eventually mutates around the drug's effectiveness. "And so we have to discover the most rational combinations and see if these combinations allow complete response," Bunn says.

In addition to therapies targeting oncogenes, Bunn describes completely new approaches to treating the disease, including Phase III clinical trials of lung cancer vaccines that aid the body's immune response against the cancer, and the search for ways to promote the function of tumor-suppressor genes that are commonly turned off in cancers.

What is clear is that after many years of chemotherapy and radiation, we're in the midst of an explosion in novel lung cancer treatment options.

"In the coming few years it is likely that we will identify additional 'actionable' molecular drivers treated with specific oral inhibitors," Bunn says. "We're already up to 30 or 40 percent of lung cancers that are susceptible to targeted therapies. I don't know if we'll reach 100 percent but the number is certain to grow."


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. Range of diagnostic spinal fluid tests needed to differentiate concurrent brain diseases
2. Triple negative breast cancer symposium highlights current advances
3. Why current strategies for fighting obesity are not working
4. Current and former smokers at risk for recurrent hepatitis post-liver transplantation
5. DMP module on heart failure: Current guidelines indicate some need for revision
6. Study suggests new way to prevent recurrent ear infections
7. Daily Aspirin May Help Those at Risk for Recurrent Blood Clots
8. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
9. Benefit of PET or PET/CT in recurrent bowel cancer is not proven
10. Study reveals how cancer drug causes diabetic-like state
11. New drug prevents spread of human prostate cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
(Date:10/12/2017)... Malvern, PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best ... New York City on October 11, 2017. , The annual award competition recognizes editorial ...
(Date:10/12/2017)... BALTIMORE (PRWEB) , ... October 12, 2017 , ... ... average of $3,296 in property taxes a year. In some states—like New York, ... higher. , By contrast, many overseas retirement havens have extremely low property-tax rates, ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform ... published the first annual edition of its Global CSR Risk and Performance ... evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data ... ... ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
(Date:9/9/2017)... 2017 Dealmed Medical Supplies, New ... equipment, supplies, drugs, vaccines, and specialty medical products and ... agreement to acquire Vantage Medical Supplies, a major distributor ... Holtsville, New York . ... emerging medical practices, will operate under the Dealmed name ...
Breaking Medicine Technology: